BR112019005542A2 - composições para compostos de agente terapêutico de pequenas moléculas - Google Patents

composições para compostos de agente terapêutico de pequenas moléculas

Info

Publication number
BR112019005542A2
BR112019005542A2 BR112019005542A BR112019005542A BR112019005542A2 BR 112019005542 A2 BR112019005542 A2 BR 112019005542A2 BR 112019005542 A BR112019005542 A BR 112019005542A BR 112019005542 A BR112019005542 A BR 112019005542A BR 112019005542 A2 BR112019005542 A2 BR 112019005542A2
Authority
BR
Brazil
Prior art keywords
therapeutic agent
small molecule
molecule therapeutic
organic acid
compositions
Prior art date
Application number
BR112019005542A
Other languages
English (en)
Inventor
A Watkins Gregory
Original Assignee
Delpor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delpor Inc filed Critical Delpor Inc
Publication of BR112019005542A2 publication Critical patent/BR112019005542A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a uma composição que compreende uma suspensão aquosa compreendendo um agente terapêutico de pequenas moléculas e um ácido orgânico. o agente terapêutico de pequenas moléculas é uma base e possui uma solubilidade em água na temperatura ambiente menor do que cerca de 1,0 g/l. o ácido orgânico possui uma solubilidade em água na temperatura ambiente entre 0,1 e 10, possui uma massa molar menor do que 500 gramas por mol e/ou mantém um ph da suspensão em seu ambiente de uso entre 3,0 a 6,5. o ácido orgânico aumenta a solubilidade do agente terapêutico de pequenas moléculas e quando presente com excesso estequiométrico, o ácido orgânico aciona a liberação do agente terapêutico de pequenas moléculas em um ambiente de uso tamponado durante períodos prolongados, por exemplo, de seis meses a um ano. os dispositivos que compreendem as composições e métodos de tratamento também são descritos.
BR112019005542A 2016-09-23 2017-09-22 composições para compostos de agente terapêutico de pequenas moléculas BR112019005542A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662399083P 2016-09-23 2016-09-23
PCT/US2017/053074 WO2018057968A1 (en) 2016-09-23 2017-09-22 Compositions for small molecule therapeutic agent compounds

Publications (1)

Publication Number Publication Date
BR112019005542A2 true BR112019005542A2 (pt) 2019-06-18

Family

ID=60083440

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005542A BR112019005542A2 (pt) 2016-09-23 2017-09-22 composições para compostos de agente terapêutico de pequenas moléculas

Country Status (10)

Country Link
US (1) US20190224322A1 (pt)
EP (1) EP3515407A1 (pt)
JP (2) JP2019529564A (pt)
KR (2) KR20230093349A (pt)
CN (1) CN109890365A (pt)
AU (1) AU2017331340B2 (pt)
BR (1) BR112019005542A2 (pt)
CA (1) CA3037531A1 (pt)
MX (2) MX2019003052A (pt)
WO (1) WO2018057968A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019228497A1 (en) * 2018-02-27 2020-09-17 Delpor, Inc. Compositions for small molecule therapeutic agent compounds
CA3149545A1 (en) * 2019-08-28 2021-03-04 Delpor, Inc. Compositions for small molecule therapeutic agent compounds
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
TWI820673B (zh) * 2021-04-13 2023-11-01 大陸商上海雲晟研新生物科技有限公司 布瑞哌唑口溶膜組合物、其製備方法及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
US7592300B2 (en) * 2003-11-24 2009-09-22 The Dial Corporation Antimicrobial compositions containing an aromatic carboxylic acid and a hydric solvent
AR048272A1 (es) * 2004-03-18 2006-04-12 Lek Pharmaceuticals Sintesis de 2 metil - 4- (4- metil -1- piperazinil) - 10 h- tieno ( 2,3-b) (1,5) benzodiazepina y sus sales, metodos para su preparacion, composiciones farmaceuticas que la contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mentales.
PL377084A1 (pl) * 2005-09-15 2007-03-19 Koźluk Tomasz Nobilus Ent Nowe związki olanzapiny i sposób ich wytwarzania
NZ584370A (en) * 2007-10-09 2011-04-29 Cipla Ltd Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes
WO2009135091A1 (en) * 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
EP3006024B1 (en) * 2009-01-20 2019-03-20 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Benzoic acid or salts thereof to enhance the activity of a neuropharmaceutical
US9561352B2 (en) 2009-03-12 2017-02-07 Delpor, Inc. Implantable device for long-term delivery of drugs
JP5664871B2 (ja) * 2009-06-19 2015-02-04 株式会社 メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
HRP20211853T1 (hr) * 2010-05-31 2022-03-04 Laboratorios Farmaceuticos Rovi, S.A. Sastavi in situ injekcijskih biorazgradivih implantata
KR101408370B1 (ko) * 2012-06-26 2014-06-18 주식회사지씨비 아리피프라졸-유기산 공결정을 함유하는 제제 및 이의 제조 방법
CA2885941A1 (en) * 2012-09-28 2014-04-03 Delpor, Inc. Device and method for sustained release of antipsychotic medications
CN106474058B (zh) * 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂

Also Published As

Publication number Publication date
KR20230093349A (ko) 2023-06-27
MX2019003052A (es) 2019-11-25
MX2023003010A (es) 2023-04-10
CN109890365A (zh) 2019-06-14
CA3037531A1 (en) 2018-03-29
US20190224322A1 (en) 2019-07-25
KR20190066608A (ko) 2019-06-13
JP2022188046A (ja) 2022-12-20
AU2017331340A1 (en) 2019-04-11
AU2017331340B2 (en) 2023-09-28
EP3515407A1 (en) 2019-07-31
WO2018057968A1 (en) 2018-03-29
JP2019529564A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
BR112019005542A2 (pt) composições para compostos de agente terapêutico de pequenas moléculas
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
BR112019024785A2 (pt) composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso
BR112014025564A2 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo
BR112014009131A2 (pt) formulações de etanercept estabilizadas com meglumina
BR112018014272A2 (pt) processo de preparação de etilenoaminas
CL2019002677A1 (es) Composición adhesiva y método de preparación de la misma.
BR112013010918B8 (pt) composição compreendendo sal de cloridrato de alumínio, método de fabricação do referido sal e usos do mesmo
BR112022010112A2 (pt) Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
BR112015023829A2 (pt) composto de amidina e seu uso
BR112018013033A2 (pt) compostos de indolinonas e seu uso no tratamentod de doenças fibróticas
BR112016025126A2 (pt) formulação líquida compreendendo composto neutralizante de gm-csf
BR112012026659A2 (pt) composto para desinfecção de superfícies.
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
NI202000031A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
BR112017005218A2 (pt) mistura de compostos, processo para fabricar uma mistura, formulação aquosa, e, uso de misturas de compostos.
UY35536A (es) ?derivados de sulfonamida?.
BR112015031998A2 (pt) formulação detergente, produto detergente, e processos para preparar uma formulação detergente
AR077371A1 (es) DERIVADOS DE PIRAZOL, SU PREPARACIoN Y SU APLICACIoN EN LA TERAPIA DEL CÁNCER
BR112015002041A2 (pt) formulação transdérmica contendo inibidores de cox
CL2017002449A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
BR112015014737A2 (pt) compostos spiroisoxazolina tendo uma atividade potencializando a atividade de um antibiótico
BR112018013429A2 (pt) ?composto, composição, método para o controle de um nematoide, utilização de uma composição e semente?
GT200500214A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]